Alkermes plc. Annual Report - Your Investor's Guide to Their Year

Considering an investment in Alkermes plc.? This summary breaks down their past year's performance, financial health, and future prospects in an accessible way, helping you understand what drives this biopharmaceutical company.

Who is Alkermes? (Business Overview)

Alkermes is a global biopharmaceutical company that develops innovative medicines for central nervous system (CNS) disorders, including psychiatric, neurological, and addiction conditions, as well as oncology. They often use complex drug delivery technologies in their approach.

Key Products & Their Impact:

• Vivitrol (naltrexone for extended-release injectable suspension): A leading treatment for alcohol and opioid dependence. It remains a significant revenue driver, though its growth is moderating.
• LYBALVI (olanzapine and samidorphan): A newer oral medication for schizophrenia and bipolar I disorder. This product is a key growth engine, with strong uptake since its launch.
• Vumerity (diroximel fumarate): An oral treatment for relapsing forms of multiple sclerosis, licensed to Biogen. Royalties from this product steadily contribute to Alkermes' revenue.
• RISPERDAL CONSTA (risperidone long-acting injection): An antipsychotic for schizophrenia and bipolar I disorder, licensed to Janssen.
• Long-Acting INVEGA Products (paliperidone palmitate): Also licensed to Janssen, these are long-acting injectable antipsychotics.
• Aristada and Aristada Initio (aripiprazole lauroxil): Long-acting injectable treatments for schizophrenia.

Beyond their own products, Alkermes also earns revenue from manufacturing services for other pharmaceutical companies and royalties on licensed medicines, diversifying its income. Their research and development (R&D) efforts primarily advance their CNS pipeline, which includes several promising candidates in various clinical trial stages.

The Money Story: Financial Performance & Financial Health (Fiscal Year Ended December 31, 2023)

Alkermes delivered robust financial performance last year, demonstrating strong growth in key areas.

• Total Revenue: The company reported total revenues of approximately $1.6 billion, a solid 8% increase over the previous fiscal year. LYBALVI and Vivitrol's strong performance primarily drove this growth.
• Product Sales: Sales of their own products, particularly LYBALVI and Vivitrol, were the main contributors, reaching $1.2 billion, a 12% increase year-over-year.
• Net Income: Alkermes achieved net income of $150 million, or $0.90 per diluted share. This significantly improved from a net loss of $50 million, or ($0.30) per diluted share, in the prior year, reflecting increased sales and disciplined expense management.
• Operating Expenses:
  • Research & Development (R&D): R&D expenses were approximately $400 million, about 25% of total revenue, reflecting continued pipeline investment.
  • Selling, General & Administrative (SG&A): SG&A expenses stood at around $650 million, or 41% of total revenue, primarily supporting LYBALVI and Vivitrol's commercialization.
• Cash Flow & Balance Sheet (Financial Health): The company generated strong operating cash flow of $300 million, indicating healthy underlying business operations. At year-end, Alkermes held approximately $750 million in cash and equivalents and had total debt of $1.0 billion, maintaining a manageable debt-to-equity ratio.

Customer Concentration: A significant portion of Alkermes' revenue comes from a few major customers, primarily large pharmaceutical distributors. For instance, the top three customers (Cencora, Cardinal Health, and McKesson) collectively accounted for approximately 45% of total revenues. While common in the pharmaceutical industry, this concentration poses a potential risk if relationships with these key partners change.

Management Discussion & Analysis Highlights

The company's financial performance reflects effective execution of its commercial strategy, particularly LYBALVI's strong uptake. The significant improvement in net income demonstrates the business model's leverage as proprietary product sales grow and disciplined expense management continues. Strong operating cash flow generation underscores the business's underlying health. A major highlight impacting the company's future strategic direction and financial structure is the recent spin-off.

• Major Corporate Development: Shortly after the fiscal year-end, a significant event occurred. On February 12, 2024, Alkermes completed the spin-off of its oncology business into Damian Therapeutics plc., a new, independent publicly traded company. This strategic move allows Alkermes to focus entirely on its core neuroscience business, while Damian Therapeutics pursues its oncology pipeline. The transaction involved new credit agreements totaling $1.5 billion to facilitate the separation and provide capital for both entities. This event significantly reshapes Alkermes' operational focus and financial profile.

Risk Factors

Investors should be aware of several risks inherent in the biopharmaceutical industry and specific to Alkermes' operations, including:

• Competition: Intense competition in the CNS and addiction markets from established and emerging therapies, including generics.
• Regulatory Approvals: The inherent uncertainty, length, and cost of drug development and regulatory approval, and the risk of failing to obtain or maintain necessary approvals.
• Patent Expiry: Potential loss of market exclusivity for key products due to future patent expirations or challenges, leading to generic competition and reduced revenues.
• Reimbursement & Pricing Pressures: Challenges related to healthcare payer policies, government regulations, and increasing pressure on drug pricing, which could impact product access and profitability.
• Clinical Trial Outcomes: The risk that ongoing clinical trials may not yield positive results, fail to meet primary endpoints, or demonstrate unexpected safety issues, leading to delays or abandonment of development programs.
• Customer Concentration: Reliance on a limited number of large pharmaceutical distributors for a significant portion of product sales.
• Integration and Operational Risks: Risks associated with the recent spin-off of the oncology business, including potential disruptions, increased costs, and the remaining neuroscience business's ability to operate effectively as a standalone entity.

Competitive Position

Alkermes operates in highly competitive markets, particularly within CNS disorders and addiction. Its competitive strengths include:

• Differentiated Product Portfolio: Innovative drug delivery technologies (e.g., long-acting injectables) differentiate its products in markets with established oral therapies, potentially improving patient adherence and outcomes.
• Market Leadership: Vivitrol holds a significant position in the alcohol and opioid dependence treatment market. LYBALVI gains traction in the schizophrenia and bipolar I disorder markets, competing with both older and newer antipsychotics by offering a differentiated profile.
• Strong R&D Capabilities: Continuous investment in research and development (R&D) aims to discover and develop novel therapies and improve existing ones, building a pipeline of potential future competitive advantages.
• Strategic Partnerships: Licensing agreements and collaborations (e.g., with Biogen, Janssen) leverage partners' commercial reach and expertise, expanding market access for Alkermes' innovations and generating royalty income.
• Intellectual Property: A robust portfolio of patents and other intellectual property protects its key products and technologies, offering market exclusivity and a barrier to entry for competitors.

However, the company faces intense competition from generic manufacturers, other branded pharmaceutical companies with similar products, and new entrants developing novel treatments. Success depends on continuous innovation, effective commercialization, securing favorable reimbursement, and managing intellectual property.

Future Outlook

Alkermes positions itself for continued growth and strategic evolution, particularly following the oncology spin-off.

• Strategic Focus: The company's primary strategic objectives include maximizing LYBALVI and Vivitrol's commercial potential, advancing its core CNS development pipeline, and optimizing operational efficiency as a pure-play neuroscience company. This focus aims to drive long-term value creation.
• Pipeline & Innovation: Alkermes continues to invest in its robust pipeline, with several clinical programs in areas like major depressive disorder and other neurological conditions. Updates on these programs, including anticipated clinical trial readouts and regulatory submissions, are expected in the coming year, potentially providing additional growth drivers.
• Outlook for 2024: Management provides guidance for fiscal year 2024, projecting total revenues in the range of $1.65 billion to $1.75 billion and adjusted diluted EPS between $1.05 and $1.20. This reflects confidence in the continued growth of their core neuroscience portfolio post-spin-off, and the company's expectations for continued commercial momentum and disciplined financial management.